발열성 호중구 감소증 시장 규모, 점유율, 성장 분석, 치료 유형별, 리스크 요인별, 약제 클래스별, 지역별 - 산업 예측(2025-2032년)

Global Febrile Neutropenia Market size was valued at USD 11.9 billion in 2023 and is poised to grow from USD 12.55 billion in 2024 to USD 19.27 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The febrile neutropenia market is primarily influenced by the rising global incidence of cancer, which escalates the risk of neutropenic complications related to chemotherapy. The increasing use of chemotherapy and immunosuppressive therapies underscores a heightened demand for effective preventive measures. Furthermore, advancements in long-acting G-CSF therapies and regulatory approvals for biosimilars enhance treatment accessibility, particularly in developed and emerging markets. However, significant challenges persist, including the high costs associated with biosimilars that hinder availability in low- and middle-income regions. Additionally, limited awareness and late diagnoses contribute to hospitalizations at more severe stages, while chronic G-CSF use raises ongoing side effects concerns. The looming fear of antibiotic resistance and regulatory uncertainties regarding biosimilar approvals further complicate the market landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Febrile Neutropenia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Febrile Neutropenia Market Segments Analysis

Global Febrile Neutropenia Market is segmented by Treatment Type, Risk Factors, Drug Class and region. Based on Treatment Type, the market is segmented into Prophylactic Treatment and Therapeutic Treatment. Based on Risk Factors, the market is segmented into Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia and Genetic Disorders. Based on Drug Class, the market is segmented into Antibiotics, Granulocyte Colony-Stimulating Factors, Antifungals and Antivirals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Febrile Neutropenia Market

A key market driver for the global febrile neutropenia market is the increasing prevalence of cancer and the growing aging population, which is more susceptible to various types of malignancies. As cancer treatments, particularly chemotherapy, become more aggressive and widespread, the risk of febrile neutropenia-a severe complication characterized by fever and low neutrophil counts-escalates. This rising incidence drives demand for effective prophylactic therapies and treatment options, fueling innovations in drug development and increasing healthcare expenditure. Additionally, heightened awareness and improved diagnostic techniques contribute to earlier detection and management of febrile neutropenia, further propelling market growth.

Restraints in the Global Febrile Neutropenia Market

One of the key market restraints for the global febrile neutropenia market is the high cost associated with the development and manufacture of innovative therapeutics and supportive care medications. This financial burden often limits accessibility for patients, particularly in low- and middle-income countries where healthcare resources are constrained. Additionally, the complexity of clinical trials and stringent regulatory approval processes can delay the introduction of new treatments, further inhibiting market growth. Furthermore, the lack of awareness and understanding of febrile neutropenia among healthcare providers may lead to underdiagnosis and under-treatment, compounding the challenges faced in this market.

Market Trends of the Global Febrile Neutropenia Market

The Global Febrile Neutropenia market is experiencing a transformative shift driven by the increased acceptance and integration of biosimilars in supportive cancer care. The growing approval of biosimilars like filgrastim and pegfilgrastim is enhancing treatment accessibility, particularly in developing markets, where cost-effective options are crucial for equitable cancer care. This trend fosters healthy competition among providers, ultimately leading to better patient outcomes and improved healthcare affordability. As healthcare systems globally adapt to these innovations, the market is poised for significant expansion, reflecting a broader commitment to increasing access to essential cancer care therapies and enhancing the quality of life for patients.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Febrile Neutropenia Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Prophylactic Treatment
• Therapeutic Treatment

Global Febrile Neutropenia Market Size by Risk Factors & CAGR (2025-2032)

• Market Overview
• Chemotherapy-Induced Neutropenia
• Transplant-Related Neutropenia
• Genetic Disorders

Global Febrile Neutropenia Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antibiotics
• Granulocyte Colony-Stimulating Factors
• Antifungals
• Antivirals

Global Febrile Neutropenia Market Size & CAGR (2025-2032)

• North America (Treatment Type, Risk Factors, Drug Class)
  • US
  • Canada
• Europe (Treatment Type, Risk Factors, Drug Class)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Risk Factors, Drug Class)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Risk Factors, Drug Class)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Risk Factors, Drug Class)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Biologics Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hanmi Pharmaceutical Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeyondSpring Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• G1 Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Partner Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellerant Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter Plc. (Hungary)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations